Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Sanara MedTech (SMTI) Research & Development (2020 - 2025)

Sanara MedTech (SMTI) has disclosed Research & Development for 6 consecutive years, with $665133.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Research & Development fell 15.14% year-over-year to $665133.0, compared with a TTM value of $6.0 million through Sep 2025, up 78.91%, and an annual FY2024 reading of $5.7 million, up 38.01% over the prior year.
  • Research & Development was $665133.0 for Q3 2025 at Sanara MedTech, down from $1.3 million in the prior quarter.
  • Across five years, Research & Development topped out at $3.0 million in Q4 2024 and bottomed at $35674.0 in Q3 2021.
  • Average Research & Development over 5 years is $884119.4, with a median of $985651.0 recorded in 2024.
  • The sharpest move saw Research & Development skyrocketed 2875.24% in 2022, then crashed 36.99% in 2023.
  • Year by year, Research & Development stood at $300837.0 in 2021, then soared by 243.71% to $1.0 million in 2022, then plummeted by 36.99% to $651519.0 in 2023, then skyrocketed by 358.56% to $3.0 million in 2024, then plummeted by 77.74% to $665133.0 in 2025.
  • Business Quant data shows Research & Development for SMTI at $665133.0 in Q3 2025, $1.3 million in Q2 2025, and $1.1 million in Q1 2025.